Skip to content
OpenCapital
Get started

Bausch Health Companies BHC Increase (Decrease) in Inventories

Increase (Decrease) in Inventories at other companies

Henry Schein logo
Henry ScheinHSIC
-$8M-157%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$1.86B-15.9%

Profitability

See full
Gross margin71.4%—
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%—
Debt / equity45.2×—
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInInventories.

The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch Health Companies's increase (decrease) in inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch Health Companies's increase (decrease) in inventories?
Bausch Health Companies (BHC) reported increase (decrease) in inventories of $14M in Q1 2026.
How has Bausch Health Companies's increase (decrease) in inventories changed year-over-year?
Bausch Health Companies's increase (decrease) in inventories decreased by 53.3% year-over-year, from $30M to $14M.
What is the long-term trend for Bausch Health Companies's increase (decrease) in inventories?
Over 2 years (2022 to 2024), Bausch Health Companies's increase (decrease) in inventories has grown at a 16.1% compound annual growth rate (CAGR), from $198M to $267M.